Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS by Vandenberghe, Peter & Beel, Karolien
[Pediatric Reports 2011; 3(s2):e9] [page 21]
Severe congenital neutropenia,
a genetically heterogeneous
disease group with an
increased risk of AML/MDS
Peter Vandenberghe,1 Karolien Beel2
1Center for Human Genetics,
Universitaire Ziekenhuizen Leuven,
Leuven, Belgium; 2Department 




Over  the  past  decade,  enormous  progress
has been made in the understanding of severe
congenital  neutropenia  (SCN),  by  identifica-
tion  of  several  causal  gene  mutations:  in
ELANE, GFI1, HAX1, WAS and G3PC3. SCN is a
preleukemic condition, independent of the ge-
netic subtype. Acquired CSF3R mutations are
specific  for  SCN  and  are  strongly  associated
with malignant progression. In this review, we
describe the known genetic subtypes of SCN,
their molecular basis and clinical presentation
and  summarize  the  available  evidence  on
CSF3R mutations and monosomy 7 in malig-
nant conversion.
Introduction
Severe congenital neutropenia (SCN) was
first described in 1956 by Rolf Kostmann as in-
fantile  genetic  agranulocytosis.1 Since  then,
almost half a century passed before ELANE mu-
tations  were  discovered  as  the  first  genetic
cause underlying SCN.2 Two years later, a new
SCN  subtype,  named  X-linked  neutropenia,
was  identified,  caused  by  gain-of-function
WAS  mutations.3 6  years  later,  HAX1 muta-
tions, underlying Kostmann syndrome or auto-
somal recessive SCN, were discovered.4 GFI1
mutations  and  G6PC3  mutations,  both  ex-
tremely rare, complete the list of causal ge-
netic mutations in SCN known today.5,6 SCN is
a rare disease, with an incidence of 1 in 200
000 births.7 SCN represents a heterogeneous
group of inherited disorders, characterized by
absolute neutrophil counts below 0.5x109/L in
the peripheral blood on 3 separate occasions
during 6 months of observation, early onset of
severe bacterial infections and a maturation
arrest  of  granulopoiesis  at  the  promyelo  -
cyte/myelocyte stage.8,9 The clinical diagnosis
is  usually  made  at  birth  or  during  the  first
months of life, based on recurrent severe in-
fections  -most  commonly  muco-cutaneous,
ear-nose-throat and pulmonary and on severely
reduced neutrophil counts.10 Much has been
learned from two large registration networks:
the Severe Chronic Neutropenia International
Registry (SCNIR), in Seattle (USA) and Han-
nover (Germany) and the French SCN registry.
The genes most commonly involved are ELANE
(in 50-60% of cases) and HAX1 (in 4-30% of
cases),  while  mutations  in  GFI1, WAS  and
G6PC3 have been described in smaller num-
bers  of  patients.3-6,9 Recently,  four  patients
with concurrent mutations in 2 of these genes
have been described, (ELANE+ HAX1, ELANE+
G6PC3 and 2 with HAX1+G6PC3), challenging
mutation analysis algorithms in SCN.11 As of
today, nearly 40% of SCN cases remain unex-
plained from a genetic point of view.12,13 For
most subtypes of SCN, increased apoptosis of
neutrophils and neutrophil precursors is con-
sidered the main underlying mechanism.12,14
Genetic subtypes
ELANE
In 1999 ELANE mutations were discovered
in cyclic neutropenia (OMIM #162800).2 Sub-
sequent  studies  revealed  that  heterozygous
mutations in the ELANE gene were found in
approximately 50% of SCN patients of Central
European  and  Northern  American  ancestry
and are the most common cause of familial
and sporadic SCN (SCN1, OMIM #202700).4
ELANE  encodes  the  serine  protease  neu-
trophil elastase, in azurophil granules in the
cytoplasm of promyelocytes and promonocytes,
where it contributes to proteolytic and antibac-
terial properties. SCN patients with an ELANE
mutation have isolated neutropenia and define
a  subset  of  SCN  with  more  severe  disease,
lower neutrophil counts and only modest re-
sponses to rG-CSF. According to some, ELANE
mutant SCN patients may also have a higher
incidence of AML/MDS.15-17
For a long time, it remained ill-understood
how  loss-of-function  ELANE  mutations  can
cause a hereditary disease with dominant in-
heritance.18 An  elegant  new  hypothesis  was
proposed,  implying  the  unfolded  protein  re-
sponse  (UPR)  in  SCN  with  ELANE  muta-
tions.19,20 Most secreted proteins in eukaryotes
fold and mature in the endoplasmic reticulum
(ER). Imbalances in the load of unfolded pro-
teins versus the handling capacity of the ER
will lead to ER stress. The UPR refers to a coor-
dinated  adaptive  program  protecting  the  cell
from  ER  stress,  by  attenuating  protein  syn-
thesis, by increasing ER handling capacity of
unfolded proteins and by degrading misfolded
proteins.20 In case of overwhelming ER stress,
apoptosis will be triggered.21 Mild UPR activa-
tion would thus lead to the less severe pheno-
type of cyclic neutropenia and increasing UPR
activation to the more severe SCN phenotype.20
GFI1
An extremely rare subtype of SCN is caused
by  autosomal  dominant  mutations  in GFI1
(growth factor independent 1) (SCN2, OMIM
#600871).  Here,  a  striking  monocytosis  and
mild lymphopenia accompany the neutropenia.
So  far,  only  one  sporadic13  and  3  familial
cases5,18 have been described. GFI1 represents
a new link in the ELANE pathway, as it encodes
a transcriptional repressor for ELANE.10 GFI1
mutations abolish binding of GFI1 to ELANE in
a dominant negative fashion, leading to upreg-
ulation of ELANE expression, postulated to in-
duce  the  UPR,  although  this  has  not  been
proved.20
HAX1
More than 50 years after Kostmann’s orig-
inal report, Klein et al. discovered HAX1 muta-
tions as the genetic cause of Kostmann’s dis-
ease, the autosomal recessive form of SCN.4
HAX1 mutations cause premature stop codons
and are loss-of-function mutations, explaining
the autosomal recessive inheritance pattern.
HAX1 is ubiquitously expressed, maintains the
inner mitochondrial membrane potential and
protects myeloid cells from apoptosis. Absence
of HAX1 leads to increased apoptosis. Patients
with Kostmann’s disease have very low neu-
trophil  counts,  usually  around  0.2x109/L.  In-
triguingly, HAX1 mutations affecting only the
full length HAX1 isoform are associated with
neutropenia only, whereas mutations affecting
the full length isoform and a short isoform are
associated with neutropenia and neurological
defects, ranging from mild cognitive impair-
ment  to  severe  developmental  delay  and/or
epilepsy, usually from the second decade. This
suggests that the shorter isoform has a func-
tion in neurological tissue.22,23 The frequency
of HAX1 mutations varies widely depending on
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the ethnic composition of the tested SCN co-
hort. Most reported patients (>22 cases) are
from consanguineous marriages from Middle-
Eastern  (Kurdish)  descent4,22,24 while  Kost-
mann first described the disease in a consan-
guineous Norwegian family.1
G6PC3
In  2008,  a  new  subtype  of  SCN  (SCN4,
OMIM  #612541),  was  identified,  caused  by
biallelic  missense  mutations  in  G6PC3.6 As
HAX1, these mutations have been discovered
in the German SCN Registry, containing a rel-
atively high number of intermarried Kurdish
immigrant families. In addition, these patients
had cardiac malformations, prominent subcu-
taneous veins or venous angiectasia, urogen-
ital malformations, inner-ear hearing loss or
delayed growth. Increased stress on the ER is
the proposed cause of the increased apoptosis.
Two new cases were recently reported.13
XLN
In  2001,  we  reported  our  discovery  of  X-
linked neutropenia (XLN).3 This rare subtype
of SCN with X-linked inheritance is caused by
gain-of-function  mutations  in  the  Wiskott-
Aldrich syndrome gene.3 These mutations are
essentially different from the loss-of-function
mutations in the classical Wiskott-Aldrich syn-
drome,  which  cause  a  triad  of  immunodefi-
ciency, thrombocytopenia and eczema. In the
original  report,  5  XLN  cases  were  described.
Since, 13 additional cases were described13,14,25
while we have 3 additional unpublished cases.
Infectious mortality is limited in the antibiotic
era.  Non-haematological  manifestations  have
not yet been observed. Distinguishing features
of XLN are monocytopenia and very low NK cell
numbers. Other features are low B-cell counts,
platelet counts in the low-normal range, inver-
sion of the CD4/CD8 ratio and IgA levels in the
low-normal range. Not all cases with XLN re-
quire hematopoietic growth factor support, but
if needed, gratifying responses are usually ob-
served to low-doses. B- and T- cell function do
not seem to be grossly abnormal.
WAS  mutations  reported  in  XLN  are  mis-
sense mutations, all positioned in exon 9 en-
coding  part  of  the  GTP-ase  binding  domain
(GBD) of the WASP protein.3,14,25 They destabi-
lize hydrophobic interactions, essential for the
auto-inhibited structure of WASP. As a result,
WAS becomes constitutively active, independ-
ently of Cdc42 and will – via Arp2/3 – induce
increased actin polymerization in vitro and in
cell-based assays.3,25,26
Two  patients  of  the  original  Belgian  XLN
family  developed  a  myeloid  malignancy.  In
both, we found CSF3R mutations in leukemic
phase.  Thus,  XLN  also  encompasses  an  in-
creased risk of conversion to a myeloid malig-
nancy, as does classical, autosomal SCN.
Activating WAS mutations strongly disturb
the  cytoskeletal  organisation  in  different  in
vitro cell models. Cell lines transfected with
mutant WASP have a diffuse F-actin pattern
and  are  significantly  smaller  than  cells  ex-
pressing  WT  WASP.  Finally,  mutant  WASP
transfected cells exhibit altered mobility pat-
terns.26 These data support the notion that an
increased  actin  polymerization  disturbs  the
function of the actin cytoskeleton, leading to a
loss of the capacity to coordinate logical and di-
rectional  cellular  movement  and  cell  migra-
tion.  The  mechanism  by  which  activating
WASP mutations cause XLN may lie in this loss
of migrational capacity of progenitor cells, who
fail  to  encounter  the  adequate  environment
and cell-cell contacts for the development into
normal granulocytes. In addition, the altered
cytoskeleton organisation may lead to genomic
instability.26,27
G-CSF, friend or foe?
Approximately 95% of SCN patients benefit
from recombinant G-CSF (rG-CSF) treatment
and  morbidity  and  mortality  have  decreased
dramatically since the availability of recombi-
nant  rG-CSF.
28-30 Before,  42%  of  the  patients
died before the age of 2 years with a median
survival of only 3 years.31 Since rG-CSF, sepsis
mortality dropped to 0.9% per year.32 However,
with longer survival of these patients, a sub-
stantial  risk  for  leukemic  conversion  has
emerged, and is an increasing reason for con-
cern.33
Even before rG-CSF, surviving patients with
SCN and with Shwachman-Diamond syndrome
were  known  to  run  an  increased  risk  of
myeloid  malignancies,34,35 although  the  true
risk  was  never  defined.  On  one  hand,  pro-
longed patient survival might merely unveil an
intrinsic  increased  risk  of  leukemic  conver-
sion.35 On the other hand, rG-CSF might be
more directly involved and act as a promoter
carcinogen, by increasing myeloid mitotic ac-
tivity or by protecting myeloid progenitors with
mutations against apoptosis.9,37,38 Even if the
role  of  rG-CSF  remains  unclear  to  date,  it
seems cautious to use it sparingly, and to titer
the dosage individually to achieve the minimal
ANC required to prevent or battle major infec-
tions.
In  2006,  the  cumulative  incidence  of
MDS/AML in 374 patients of the SCNIR was re-
ported 21% after 10 years and 34% after 15
years of rG-CSF treatment.17,32 In a more re-
cent report, a cumulative incidence of malig-
nant transformation in SCN of more than 25%
after 20 years of observation was reported. The
malignancies  were  predominantly  AML,  but
ALL, CMML and MDS have also been observed.
A subgroup of patients was defined with appar-
ently more severe disease and with poor re-
sponsiveness to rG-CSF, despite a rG-CSF dose
of more than 8 µg/kg/day.32 This subgroup had
a 2-fold increase in risk of death from sepsis
and  a  cumulative  incidence  of  malignant
transformation as high as 40% after 10 years.32
Mutations in the part of the G-CSF receptor
gene (CSF3R), encoding the intracellular do-
main of the G-CSFR were first reported in SCN
in 1994, and then incorrectly considered the
cause of SCN.39,40 Later it became clear that
these  mutations  are  not  inherited  but  ac-
quired, in patients defining a subgroup at high
risk  for  leukemic  conversion.37,41,42 The  fre-
quency of CSF3R mutations in SCN patients
with leukemic transformation is 78% in both
ELANE and HAX1 positive patients, whereas in
SCN patients without leukemia, the frequency
of CSF3R mutations is only 30%.9
CSF3R mutations in SCN are truncating mu-
tations, leading to the loss of regulators in the
carboxyterminal  part  of  the  intracellular  do-
main of the receptor, while the N-terminal re-
gion is important for granulocyte proliferation,
associated with loss of maturation and differ-
entiation signals. As in many types of cancer,
STAT5 plays an important role in this prolifer-
ative dominance.
CSF3R  mutations  have  been  described  in
SCN patients without progression to leukemia
and  some  SCN  patients  develop  leukaemia
without  CSF3R  mutations.  Therefore,  CSF3R
mutations are not sufficient nor required for
malignant conversion.37 The exact role of rG-
CSF in the development of CSF3R mutations
and  in  leukemic  progression  remains  un-
known. In SCN, the acquisition of a CSF3R mu-
tation in SCN mostly occurs prior to malignant
transformation.37 Therefore, CSF3R mutations
are considered promoter mutations, giving a
growth advantage to a premalignant clone, es-
pecially  in  the  presence  of  rG-CSF  treat-
ment.43,44
A directly mutagenic effect seems unlikely,
as CSF3R mutations can occur in the absence
of  prior  rG-CSF  treatment.  Moreover,  malig-
nant conversion and CSF3R mutations are not
seen with prolonged rG-CSF use in cyclic neu-
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tropenia and patients with SDS, despite treat-
ment with rG-CSF. Eight cases with HAX1 mu-
tations and with CSF3R mutations have been
described, one of whom developed myelodys-
plasia.4,9 We  have  described  two  XLN  cases
with  CSF3R  mutations  and  myeloid  malig-
nancy.45
Chromosome 7
Monosomy of chromosome 7(q) is among
the most common cytogenetic aberrations in
de novo and secondary AML and MDS and is
associated  with  an  unfavourable  prognosis.
Loss of 7(q) is also associated with an array of
congenital  bone  marrow  failure  syndromes,
that  carry  an  intrinsic  high  risk  of  myeloid
leukemia, including Fanconi anemia, Shwach  -
man-Diamond  syndrome,  neurofibromatosis
and  SCN.  In  different  subtypes  of  SCN,  pa-
tients  were  reported  with  CSF3R  mutations
and monosomy 7.44-47 A possible link between
CSF3R  mutations  and  monosomy  7(q)  was
suggested by the fact that monosomy 7 cells
are reportedly more sensitive to high doses of
rG-CSF  and  that  rG-CSF  therapy  likely  pro-
motes  selective  expansion  of  a  pre-existing
monosomy 7 clone.48 The acquisition of mono-
somy 7 is a reason to proceed to urgent stem
cell transplantation.9
Conclusions
Major strides in the insights of SCN have
been made in the last decade. However, 40% of
SCN  patients  still  have  unknown  muta-
tions.12,13 Identification  of  new  mutations  is
expected in the near future, with increasing
use of high-throughput parallel sequencing.
The risk of MDS/AML is increased in SCN,
independent  of  the  genetic  background  and
leukemic  conversion  in  all  subtypes  of  SCN
seems associated with CSF3R mutations and
monosomy 7(q), in a final common pathway.
Although the exact sequence of events in the
development of leukemia in SCN patients re-
mains unclear, these genetic aberrations are
diagnostically useful to identify a subgroup of
patients  with  a  highly  increased  risk  of
AML/MDS and in need of urgent therapeutic
intervention. It remains prudent to use rG-CSF
at the minimal dosage required to reach a safe
absolute neutrophil count.
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